Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Summary Boston Scientific came up short on margins in the fourth quarter, but reassuring guidance on revenue and improved margins in FY'23 seems to have smoothed that over. Boston Scientific has an above-average forward growth profile among larger med-techs, with multiple drivers includ...
Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference PR Newswire MARLBOROUGH, Mass. , Feb. 13, 2023 ...
Summary After years of struggling to make real progress in its core atherectomy businesses, CSII is selling out to Abbott for $20/share in cash. Abbott is acquiring an established but likely slower-growing atherectomy business that has been disrupted by ShockWave's entry into the periph...
BOSTON SCIENTIFIC INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Boston Scientific Corporation - BSX BOSTON SCIENTIFIC INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swic...
The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Boston Scientific ( NYSE: BSX ) LithoVue Elite Single-Use Digital Flexible Ureteroscope System. The company said the device is the first ureteroscope system which monitors intrarenal pressure in real-time during u...
Boston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System PR Newswire New technology designed to help inform real-time clinical decisions during kidney stone procedures MARLBOROUGH, Mass. , Feb. 3, 202...
Boston Scientific Corporation (BSX) Q4 2022 Results Conference Call February 01, 2023 08:00 AM EST Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President &...
Boston Scientific Corporation ( NYSE: BSX ) shares edged lower in the pre-market trading Wednesday after reporting Q4 2022 earnings that fell short of the company’s own guidance and Wall Street forecasts. The medical device maker failed to meet its quarterly guidance for GA...
Boston Scientific press release ( NYSE: BSX ): Q4 Non-GAAP EPS of $0.45 misses by $0.02 . Revenue of $3.24B (+3.5% Y/Y) in-line. Reported net sales of $3.242 billion, representing an increase of 3.7 percent on a reported basis, compared to the company's guidance range of 2...
News, Short Squeeze, Breakout and More Instantly...
Boston Scientific Corporation Company Name:
BSX Stock Symbol:
NYSE Market:
Boston Scientific Corporation Website:
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Boston Scientific Announces Results for Second Quarter 2024 PR Newswire MARLBOROUGH, Mass. , July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent ...
Shares of Boston Scientific Corporation (NYSE: BSX) traded at a new 52-week high today and are currently trading at $78.31. So far today, approximately 1.5M shares have been exchanged, as compared to an average 30-day volume of 5.37M shares. Boston Scientific Corporation develops, manufacture...